The presentation, titled "A CD2-based costimulatory T cell engager platform integrating a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking," highlights the company's proprietary approach to TCE development. The research focuses on addressing the clinical challenges associated with T cell engagers by utilizing specific CD3 sequences designed to minimize cytokine release syndrome while maintaining efficacy.

This technology is part of the broader AnTenGager platform, which employs a "2+1" bivalent binding mechanism. Antengene is currently advancing several programs through this pipeline, targeting conditions ranging from solid tumors to hematological malignancies. The SITC 2026 meeting, held from November 4 to 8, serves as a primary venue for the company to showcase these developments to the global oncology and immunology research community.